Lymphatic Osteopathic Manipulative Medicine to Enhance COVID-19 Vaccination Efficacy

Rowan University1 site in 1 countryFebruary 14, 2021

ConditionsCOVID-19

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: COVID-19
Sponsor: Rowan University
Locations: 1
Primary Endpoint: severe acute respiratory syndrome-associated coronavirus 2 (SARS-Cov-2) antibody levels
Status: Withdrawn
Last Updated: 3 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this project is to study the impact of Osteopathic Manipulative Medicine (OMM) treatments, such as lymphatic myofascial release and thoracic pump techniques severe acute respiratory syndrome-associated coronavirus 2 (SARS-Cov-2) antibody levels in patients who receive the mRNA-1273 (Moderna) COVID-19 vaccine and to consider if these OMM strategies allow a stronger more robust immune response.

Registry

clinicaltrials.gov

Start Date

February 14, 2021

End Date

February 28, 2023

Last Updated

3 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Rowan University

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Inclusion criteria will include age greater than 18 years old and having safely received the COVID-19 vaccine.

Exclusion Criteria

•Exclusion criteria will include age under 18 years old, malignancy/cancer, ongoing infection, coagulopathy history, use of anticoagulant medications, and fracture or acute injury of the torso neck or upper extremities. Lymphatic OMM is safe during pregnancy and this does not need to be an exclusion criteria.

Outcomes

Primary Outcomes

severe acute respiratory syndrome-associated coronavirus 2 (SARS-Cov-2) antibody levels

Time Frame: The day of first vaccine dose (baseline), the day of second vaccine dose (at about 4-weeks post first vaccine dose), and 2-weeks post second vaccine dose (at about 6-weeks post first vaccine dose

Antibody levels collected via blood draw